Table 5.
Outcome | Total | NLTX | Placebo | P value |
---|---|---|---|---|
n = 27 | n = 27 | |||
Abnormality | ||||
Loss of consciousness | 10 (18.5%) | 0 (0.0%) | 10 (37.0%) | <0.01* |
Bradypnea | 11 (20.4%) | 0 (0.0%) | 11 (40.7%) | <0.01* |
Apnea | 5 (9.3%) | 0 (0.0%) | 5 (18.5%) | 0.02* |
ABG | ||||
Respiratory acidosis & hypercapnia | 8 (14.8%) | 1 (3.7%) | 7 (25.9%) | 0.05** |
Hypoxia | 9 (16.7%) | 1 (3.7%) | 8 (29.6%) | 0.02** |
Taking naloxone bolus | 13 (24.1%) | 1 (3.7%) | 12 (44.4%) | <0.01* |
Other clinical status | ||||
Naloxone iv Infusion | 10 (18.5%) | 0 (0.0%) | 10 (37.0%) | <0.01* |
Need for ICU care | 14 (25.9%) | 0 (0.0%) | 14 (51.9%) | <0.01* |
Hospital staying (hrs) | ||||
Mean ± SD | 32 ± 20 | 26 ± 17 | 38 ± 21 | 0.009‡ |
Median (range) | 24 (12 to 96) | 20 (14 to 96) | 32 (12 to 96) |
*Based on Chi-Square test. **Based on Fisher's exact test. ‡Based on Mann-Whitney U test.